{"id":"NCT00295750","sponsor":"Ferring Pharmaceuticals","briefTitle":"The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer","officialTitle":"An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOTÂ® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2007-10","completion":"2007-10","firstPosted":"2006-02-24","resultsPosted":"2009-04-16","lastUpdate":"2012-12-19"},"enrollment":620,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":["FE200486"]},{"type":"DRUG","name":"Degarelix","otherNames":["FE 200486"]},{"type":"DRUG","name":"Leuprolide 7.5 mg","otherNames":["Lupron"]}],"arms":[{"label":"degarelix 240/160 mg","type":"EXPERIMENTAL"},{"label":"degarelix 240/80 mg","type":"EXPERIMENTAL"},{"label":"Leuprolide 7.5 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The study was a three-arm, active-control, multi-centre, parallel group study.","primaryOutcome":{"measure":"Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364","timeFrame":"12 months","effectByArm":[{"arm":"Degarelix 240/160 mg","deltaMin":98.3,"sd":null},{"arm":"Degarelix 240/80 mg","deltaMin":97.2,"sd":null},{"arm":"Leuprolide 7.5 mg","deltaMin":96.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States","Canada","Czechia","Germany","Hungary","Mexico","Netherlands","Puerto Rico","Romania","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":["19035858","34350976"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24},"commonTop":["Hot flush","Injection site pain","Injection site erythema","Weight increased","Alanine aminotransferase increased"]}}